Exp Biol Med:间叶基质干细胞有癌化潜能

2014-02-07 美文 美国科学促进会

位于荷兰鹿特丹伊拉斯姆斯大学医学中心,由潘博士及吕克•范德拉恩博士所领导的研究团队发现了人类间叶基质干细胞可以在细胞培养扩增的过程中产生自发性的癌化转变。虽然这样的转变发生的频率相当的低且常常只有在大量的继代培养才可以观察的到。这项报告发表在2014年一月的《实验生物医学杂志》。 目前,许多研究试图利用间叶基质干细胞当作治疗疾病的一种疗法。根据临床试验资料库的统计,截至2013年为止,已有超过3

位于荷兰鹿特丹伊拉斯姆斯大学医学中心,由潘博士及吕克•范德拉恩博士所领导的研究团队发现了人类间叶基质干细胞可以在细胞培养扩增的过程中产生自发性的癌化转变。虽然这样的转变发生的频率相当的低且常常只有在大量的继代培养才可以观察的到。这项报告发表在2014年一月的《实验生物医学杂志》。

目前,许多研究试图利用间叶基质干细胞当作治疗疾病的一种疗法。根据临床试验资料库的统计,截至2013年为止,已有超过350件使用间叶基质干细胞的临床试验被注册(以关键字间叶基质干细胞作为搜寻)。为了细胞移植的目的,间叶基质干细胞常常不是从病人就是从第三方的捐赠者分离出来,接着在治疗应用前以细胞培养的方式扩增。事实上,过去几十年来,原代细胞在细胞培养中自发性的转变一直被充分的研究。最近,老鼠和猴子的间叶基质干细胞的恶性转变也有被报导。

目前的研究确认了人类间叶基质干细胞自发性的癌化转变会在细胞培养扩增的过程中发生。这项研究对于体外扩增的间叶基质干细胞的临床应用潜在性地具有极大的意涵。此项研究的第一作者潘博士忧心的提到:“虽然这样的转变是少见的,但在移植到病人身上之前,我们的确需要小心的检测在间叶基质干细胞培养的过程中这些不正常细胞的存在。”资深作者吕克•范德拉恩博士说道:“我们现在已经证实了一些核糖核酸分子可以作为侦测这些因长期培养而产生的危险细胞是具有潜能的生物标记。然而,还需要更进一步的研究去证实这些生物标记可以用于临床试验中所使用的间叶基质干细胞。”

《实验生物医学杂志》的主编史蒂芬。古德曼博士说:“这项研究对于检测扩增的人类干细胞的安全性提供了可能的方法,并且我们也期待这些核糖核酸生物标记的证实。”

原文出处:
Pan Q, Fouraschen SM, Ruiter PE, Dinjens WN, Kwekkeboom J, Tilanus HW, Laan LJ.Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells.Exp Biol Med (Maywood). 2014 Jan 1;239(1):105-15. doi: 10.1177/1535370213506802. Epub 2013 Nov 13.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766864, encodeId=7a811e6686407, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Aug 10 13:20:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917023, encodeId=61a8191e0234a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 28 14:20:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757032, encodeId=035b1e570320f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sun Mar 23 05:20:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606106, encodeId=f8b016061069f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 09 02:20:00 CST 2014, time=2014-02-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766864, encodeId=7a811e6686407, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Aug 10 13:20:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917023, encodeId=61a8191e0234a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 28 14:20:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757032, encodeId=035b1e570320f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sun Mar 23 05:20:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606106, encodeId=f8b016061069f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 09 02:20:00 CST 2014, time=2014-02-09, status=1, ipAttribution=)]
    2014-04-28 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766864, encodeId=7a811e6686407, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Aug 10 13:20:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917023, encodeId=61a8191e0234a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 28 14:20:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757032, encodeId=035b1e570320f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sun Mar 23 05:20:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606106, encodeId=f8b016061069f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 09 02:20:00 CST 2014, time=2014-02-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766864, encodeId=7a811e6686407, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Aug 10 13:20:00 CST 2014, time=2014-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917023, encodeId=61a8191e0234a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 28 14:20:00 CST 2014, time=2014-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757032, encodeId=035b1e570320f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sun Mar 23 05:20:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606106, encodeId=f8b016061069f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 09 02:20:00 CST 2014, time=2014-02-09, status=1, ipAttribution=)]